The test can be used to detect HDV infection, a particularly dangerous coinfection that can occur with hepatitis B virus.
Mirum Pharmaceuticals acquires Bluejay Therapeutics, focusing on brelovitug for chronic hepatitis delta virus (HDV), a severe ...
In January 2026, Vir Biotechnology reported new positive data from its ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta, where combination therapy with investigational agents tobevibart and ...
– New data presented at AASLD The Liver Meeting. Investor conference call November 19, 2024, at 5.15 a.m. PT / 8.15 a.m. ET – SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today ...
Mirum Pharmaceuticals has entered a definitive agreement to acquire Bluejay Therapeutics — a deal that, if finalized, would add brelovitug, a phase 3-stage monoclonal antibody for chronic hepatitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results